company background image
688076 logo

Jiangsu Sinopep-Allsino Biopharmaceutical SHSE:688076 Stock Report

Last Price

CN¥69.34

Market Cap

CN¥15.1b

7D

-4.8%

1Y

99.2%

Updated

12 Jul, 2024

Data

Company Financials +

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

SHSE:688076 Stock Report

Market Cap: CN¥15.1b

688076 Stock Overview

A biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China.

688076 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance3/6
Financial Health5/6
Dividends1/6

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jiangsu Sinopep-Allsino Biopharmaceutical
Historical stock prices
Current Share PriceCN¥69.34
52 Week HighCN¥81.50
52 Week LowCN¥27.49
Beta0.35
11 Month Change11.34%
3 Month Change33.47%
1 Year Change99.20%
33 Year Change21.91%
5 Year Changen/a
Change since IPO-10.53%

Recent News & Updates

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jun 23
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Recent updates

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jun 23
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 04
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Mar 04
There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Shareholder Returns

688076CN PharmaceuticalsCN Market
7D-4.8%2.1%1.6%
1Y99.2%-16.4%-18.4%

Return vs Industry: 688076 exceeded the CN Pharmaceuticals industry which returned -16.4% over the past year.

Return vs Market: 688076 exceeded the CN Market which returned -18.4% over the past year.

Price Volatility

Is 688076's price volatile compared to industry and market?
688076 volatility
688076 Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.3%

Stable Share Price: 688076's share price has been volatile over the past 3 months.

Volatility Over Time: 688076's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,545n/awww.sinopep.com.cn

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates.

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Fundamentals Summary

How do Jiangsu Sinopep-Allsino Biopharmaceutical's earnings and revenue compare to its market cap?
688076 fundamental statistics
Market capCN¥15.13b
Earnings (TTM)CN¥208.25m
Revenue (TTM)CN¥1.18b

72.7x

P/E Ratio

12.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688076 income statement (TTM)
RevenueCN¥1.18b
Cost of RevenueCN¥469.06m
Gross ProfitCN¥712.24m
Other ExpensesCN¥503.99m
EarningsCN¥208.25m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)0.95
Gross Margin60.29%
Net Profit Margin17.63%
Debt/Equity Ratio45.8%

How did 688076 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

41%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.